Home
HelpTest ID MUM1B MUM-1/IRF4 Immunostain, Bone Marrow, Technical Component Only
Ordering Guidance
This test includes only technical performance of the stain (no pathologist interpretation is performed). If diagnostic consultation by a pathologist is required order PATHC / Pathology Consultation.
Shipping Instructions
Attach the green pathology address label and the pink Immunostain Technical Only label included in the kit to the outside of the transport container.
Specimen Required
Specimen Type: Tissue
Supplies: Immunostain Technical Only Envelope (T693)
Container/Tube: Immunostain Technical Only Envelope
Preferred:
-Formalin-fixed, paraffin-embedded tissue block
OR
-2 Unstained, positively charged glass slides (25- x 75- x 1-mm) per test ordered; sections 4-microns thick
Acceptable: None
Forms
If not ordering electronically, complete, print, and send a Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763) with the specimen.
Useful For
Aiding in the identification of hematolymphoid neoplasms and melanomas
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| IHTOI | IHC Initial, Tech Only | No | No |
| IHTOA | IHC Additional, Tech Only | No | No |
Method Name
Immunohistochemistry (IHC)
Reporting Name
Bone Marrow MUM-1/IRF4 IHC, T OnlySpecimen Type
TECHONLYSpecimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| TECHONLY | Ambient (preferred) | ||
| Refrigerated | |||
Clinical Information
MUM-1 (multiple myeloma oncogene-1), expressed by the IRF4 gene, is seen in a subset of B cells in the light zone of the germinal center (representing late stages of B cell differentiation), plasma cells, activated T cells, and a variety of hematolymphoid neoplasms derived from these cells. Among non-hematolymphoid neoplasms, MUM-1 expression has been reported in melanomas. A separate protocol optimized for B5 fixed/decalcified bone marrow specimens has been validated.
Interpretation
This test does not include pathologist interpretation, only technical performance of the stain. If interpretation is required, order PATHC / Pathology Consultation for a full diagnostic evaluation or second opinion of the case.
The positive and negative controls are verified as showing appropriate immunoreactivity and documentation is retained at Mayo Clinic Rochester. If a control tissue is not included on the slide, a scanned image of the relevant quality control tissue is available upon request, call 855-516-8404.
Interpretation of this test should be performed in the context of the patient's clinical history and other diagnostic tests by a qualified pathologist.
Clinical Reference
1. Rada G, Nagla S, Ali G: MUM1 and Ki67 Expression Best Predictors of Treatment Response in Diffuse Large B Cell Lymphoma Not Otherwise Specified. Amer J Clin Pathol. 2015 Oct;144(2,1):A147
2. Cozzolino I, Varone V, Picardi M, et al: CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples. Cancer Cytopathol. 2016 Feb;124(2):135-143. doi:10.1002/cncy.21626
3. Heo MH, Park HY, Ko YH, Kim WS, Kim SJ: IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. J Cancer. 2017 Mar;8(6):1018-1024. doi: 10.7150/jca.17358
Day(s) Performed
Monday through Friday
Report Available
1 to 3 daysTest Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
88342-TC, primary
88341-TC, if additional IHC
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| MUM1B | Bone Marrow MUM-1/IRF4 IHC, T Only | Order only;no result |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 603218 | Bone Marrow MUM-1/IRF4 IHC, T Only | Bill only; no result |
mcl-ihc